To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Subscribe To Our Newsletter & Stay Updated
